Displaying drugs 1501 - 1525 of 2861 in total
SQ-109
SQ-109 is an orally active, small molecule antibiotic for treatment of pulmonary TB. Currently in Phase I clinical trials, SQ-109 could replace one or more drugs in the current first-line TB drug regimen, simplify therapy, and shorten the TB treatment regimen.
Investigational
PR-104
Investigational
PX-102
PX-102 is under investigation in clinical trial NCT01998672 (Multiple Ascending Oral Dose Phase I Study With Px-102).
Investigational
PI-103
PI-103 is an inhibitor of p110α of class I PI3K.
Investigational
Matched Iupac: … 3-[6-(morpholin-4-yl)-8-oxa-3,5,10-triazatricyclo[7.4.0.0^{2,7}]trideca-1(13),2,4,6,9,11-hexaen-4-yl] …
GI-101
GI-101 is a bi-specific fragment crystallizable region (Fc) fusion protein containing a cluster of differentiation 80 ectodomain as an N-terminal moiety and interleukin-2 variant as a C-terminal moiety conjugated with human immunoglobulin G4 Fc.
Investigational
SP-101
Investigational
CM-101
Investigational
GS-100
GS-100 is an adeno-associated virus serotype 9 virus particle containing viral DNA that includes an expression cassette containing the human NGLY1 gene coding sequence
Investigational
Matched Description: … GS-100 is an adeno-associated virus serotype 9 virus particle containing viral DNA that includes an expression …
Lerodalcibep
Lerodalcibep is under investigation in clinical trial NCT05004675 (Trial to Evaluate Efficacy and Safety of LIB003 and Inclisiran in High-risk CVD Patients).
Investigational
Matched Synonyms: … Engineered binding protein (1-96) anti-(human proprotein convertase subtilisin/kexin type 9), derived ... Protein lib003 (recombinant human proprotein convertase subtilisin/kexin type 9 ligand-binding tenth …
Efonidipine
Efonidipine is a calcium channel blocker of the dihydropyridine class, commercialized by Shionogi & Co. (Japan). Initially, it was marketed in 1995 under the trade name, Landel. The drug has been shown to block T-type in addition to L-type calcium channels [A7844, A32001]. It has also been studied in atherosclerosis...
Experimental
AUM-302
Investigational
Matched Synonyms: … trimetheno-12H-pyrimido[5,4-j][1,9,2,5,17]dithiatriazacyclotricosin-19-one, 17-fluoro-20,21-dihydro-10 …
Matched Iupac: … 6,8,15,23,26-pentaazahexacyclo[22.3.1.1^{2,5}.1^{10,13}.1^{17,21}.0^{4,9}]hentriaconta-1(27),2(31),4(9) …
Matched Iupac: … 6,8,15,23,26-pentaazahexacyclo[22.3.1.1^{2,5}.1^{10,13}.1^{17,21}.0^{4,9}]hentriaconta-1(27),2(31),4(9) …
LAX-101
LAX-101 treats hungtington’s disease, not just the symptoms but the disease itself. The active molecule in LAX-101 is Eicosapentaenoic Acid (EPA). All molecules of EPA are identical. The molecules of EPA found in LAX-101 are identical to the molecules of EPA found in fish oil food supplements.
Investigational
FP-1096
FP1096 reduced the painful symptoms of endometriosis in trial subjects with very minimal side effect.
Investigational
SOT-107
SOT-107 is a drug that is a combination of a protein called transferrin and a poison called diphtheria toxin. This drug treat for a type of brain cancer called a high grade glioma brain tumour. About half of all brain tumours are gliomas.
Investigational
ATL-104
ATL-104 is a potent mitogen for epithelial cells of the gastrointestinal tract. In animal models, ATL-104 aids regeneration of the gastrointestinal tract after treatment with chemotherapeutic agents.
Investigational
EVT-101
Investigational
CI-1040
CI-1040 has been used in trials studying the treatment of Lung Cancer, Breast Cancer, Breast Neoplasms, Pancreatic Cancer, and Colorectal Cancer, among others.
Investigational
WP-1066
WP1066 has been used in trials studying the treatment of Melanoma, Brain Cancer, Solid Tumors, and Central Nervous System Neoplasms.
Investigational
MK-1064
MK-1064 is under investigation in clinical trial NCT02549014 (A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of MK-1064 (MK-1064-001)).
Investigational
TZP-102
TZP-102 is under investigation in clinical trial NCT01452815 (Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis).
Investigational
AIM-102
AIM-102 is under investigation in clinical trial NCT01501942 (Efficacy, Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Oral Administration of AIM-102 in Patients With Mild to Moderate Allergic Asthma).
Investigational
PHI-101
Investigational
GCS-100
Investigational
NZ-1002
Investigational
Displaying drugs 1501 - 1525 of 2861 in total